Sponsor Overview
Explore verified public information about Purdue Pharma L.P.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 2 supporting sources.
“All of the following criteria must be met in order to be considered for expanded access to Purdue’s investigational medicines: 1. The patient has a serious or immediately life-threatening disease or condition. 2. There is no comparable or satisfactory alternative therapy for the disease or condition, or the patient has undergone appropriate standard treatment without success. 3. The patient is ineligible for participation in any ongoing clinical study of the investigational medicine. 4. There is sufficient evidence or understanding of a potential patient benefit from the use of the investigational medicine to justify its potential risks. 5. The medicine must be part of an active and ongoing development process, and expanded access would not interfere within its development. 6. There is an adequate supply of the medicine to perform necessary clinical studies as well as provide expanded access.”
“Purdue Pharma is committed to advancing the medical care of patients with quality pharmaceutical products. We are known for our pioneering research in pain, a principal cause of human suffering. Today, we work with new partners on innovative healthcare solutions in many therapeutic areas. In rare cases when patients do not qualify for clinical trials and have exhausted all available treatment options, regulators may grant permission for Purdue to provide a treating physician with an unapproved medicine. Such individual use of an unlicensed investigational medicine is often called “compassionate use” or “expanded access” but may go by other names.”
Reagan-Udall Foundation Insights
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.